(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 28.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.55%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.39%.
Apellis Pharmaceuticals's revenue in 2024 is $628,786,000.On average, 9 Wall Street analysts forecast APLS's revenue for 2024 to be $96,568,369,383, with the lowest APLS revenue forecast at $92,812,730,528, and the highest APLS revenue forecast at $99,014,289,613. On average, 9 Wall Street analysts forecast APLS's revenue for 2025 to be $122,744,111,614, with the lowest APLS revenue forecast at $111,326,083,037, and the highest APLS revenue forecast at $147,093,724,224.
In 2026, APLS is forecast to generate $163,344,780,125 in revenue, with the lowest revenue forecast at $138,862,320,451 and the highest revenue forecast at $213,091,074,000.